Drug Trial Radar · NCT06763926
Intranasal Nafarelin For Triggering Oocyte Maturation
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Jan 15, 2028
Study completion Jan 15, 2028
Sponsor
- Lead sponsor
- Fundacion DexeusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.
Conditions
- Fertility Preservation
Interventions
Subcutaneous TriptorelinDrug
Women undergoing fertility preservation will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit.. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion. Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms. n the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection.
Intranasal nafarelinDrug
Women undergoing fertility preservation will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion. Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of MII (metaphase 2) oocyte retrievedTime frame: Until study completion - average of 10-20 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus
Barcelona, Spain · Recruiting
Dexeus Mujer Tarragona
Tarragona, Spain · Not yet recruiting
Dexeus Mujer Sabadell
Sabadell, Barcelona, Spain · Not yet recruiting
Dexeus Mujer Sant Cugat
Sant Cugat del Vallès, Barcelona, Spain · Not yet recruiting
Dexeus Mujer Reus
Reus, Tarragona, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.